25,050 Shares in Sanuwave Health Inc. $SNWV Bought by Evernest Financial Advisors LLC

Key Points

• Evernest Financial Advisors LLC purchased 25,050 shares of Sanuwave Health Inc., valued at approximately $823,000, constituting 0.29% of the company's stock by the end of the recent quarter.
• Several institutional investors, including Solas Capital Management LLC and AWM Investment Company Inc., have recently added significant positions in Sanuwave Health, indicating heightened interest in the stock.
• Analysts have mixed views on Sanuwave Health, with a consensus rating of "Moderate Buy" and a target price of $54.00, though Weiss Ratings has issued a "sell" rating.

Evernest Financial Advisors LLC purchased a new position in shares of Sanuwave Health Inc. (NASDAQ:SNWV - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,050 shares of the company's stock, valued at approximately $823,000. Evernest Financial Advisors LLC owned 0.29% of Sanuwave Health at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Solas Capital Management LLC acquired a new position in Sanuwave Health in the 1st quarter worth $20,658,000. AWM Investment Company Inc. acquired a new position in Sanuwave Health in the 1st quarter worth $18,153,000. Goldman Sachs Group Inc. acquired a new position in Sanuwave Health in the 1st quarter worth $337,000. Finally, Strategic Investment Solutions Inc. IL acquired a new position in Sanuwave Health in the 1st quarter worth $47,000. Institutional investors and hedge funds own 42.53% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the stock. Weiss Ratings reiterated a "sell (d-)" rating on shares of Sanuwave Health in a report on Wednesday, October 8th. Roth Capital set a $53.00 price objective on shares of Sanuwave Health and gave the stock a "buy" rating in a report on Tuesday, October 7th. Wall Street Zen lowered shares of Sanuwave Health from a "buy" rating to a "hold" rating in a report on Saturday, October 11th. Northland Capmk upgraded shares of Sanuwave Health to a "strong-buy" rating in a research note on Wednesday, September 3rd. Finally, Northland Securities started coverage on shares of Sanuwave Health in a research note on Wednesday, September 3rd. They issued an "outperform" rating and a $55.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Sanuwave Health has a consensus rating of "Moderate Buy" and a consensus price target of $54.00.

Sanuwave Health Stock Performance

Shares of Sanuwave Health stock opened at $33.30 on Thursday. The firm has a market cap of $285.38 million, a PE ratio of -4.04 and a beta of 1.33. The firm's 50-day simple moving average is $37.33 and its 200-day simple moving average is $33.68. Sanuwave Health Inc. has a 1 year low of $5.63 and a 1 year high of $46.58.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.10. The company had revenue of $10.16 million during the quarter, compared to analyst estimates of $10.14 million. Sanuwave Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS.

Sanuwave Health Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.